109 results about "Surface protein" patented technology

The invention provides a polypeptide, and the sequence of the polypeptide is AEDVGDVAFVKNDT. The polypeptide provided by the invention can inhibit the human respiratory syncytial virus surface protein F so as to inhibit the fusion of the human respiratory syncytial virus surface protein F and a host cell membrane. The invention also provides the sheep colostrum. The sheep colostrum comprises the polypeptide with the antiviral function, so that the sheep colostrum is helpful for old people with relatively weak resistance to resist infection of human respiratory syncytial viruses and promotes repair of respiratory mucosa. The invention also provides a preparation method of the sheep colostrum. The preparation method is simple and can be used for industrial production. The invention also provides a preparation method of the polypeptide.

The application discloses a kind of fowl secretory bacterium surface proteins and its screening method and application, belong to biotechnology field.The application can be soluble high-efficiency expression in escherichia coli by screening protective antigen from fowl secretory bacterium heparin binding protein, combined with antigen prediction, soluble analysis and structure-oriented protein design, successfully obtained protein A0A3Q9GGY1, A0A3S9QKJ0 and six-site mutant PLO that can be soluble high-efficiency expression in escherichia coli, has good immunoprotective efficiency, and has accumulated experience for the screening and design of high-yield antigen, and has laid a foundation for the research and development of fowl secretory bacterium vaccine.

Providing nucleic acid constructs that enhance antigen-specific immune responses against enveloped viruses. [Solution] A nucleic acid construct comprising a polynucleotide encoding a SNARE protein selected from the group consisting of VAMP7, STX7, GOSR1, and SEC22B, and a polynucleotide encoding a surface protein antigen of an enveloped virus.

A hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

The invention discloses a preparation method of a Ca (OH) 2 activated fish scale-based adsorbent, and relates to the technical field of functional materials. Comprising the following steps: 1, pretreating fish scales: carrying out acid treatment on the cleaned and dried fish scales to obtain fish scales without surface protein, carrying out alkali treatment on the fish scales to obtain fish scale slurry, drying the fish scale slurry to obtain fish scale powder, and 2, dissolving the fish scale powder and Ca (OH) 2 in water according to a mass ratio of the fish scale powder to Ca (OH) 2 of 1: 3-3: 1, adding pyrrole, fully mixing, and carrying out drying to obtain the fish scale powder. The mass volume ratio of the fish scale powder to pyrrole is (1: 8)-(1: 2), and the volume ratio of pyrrole to the potassium persulfate aqueous solution is (3: 20)-(3: 5), and step 3, carrying out suction filtration and solid-liquid separation on the composite product, repeatedly washing to be neutral, and drying to obtain the polypyrrole composite Ca (OH) 2 activated fish scale-based adsorbent.

A cell exosome, which contains, on the membrane surface thereof, one or more phospholipids of a high-fluidity liposome and a surface protein of a cancer cell.

The invention relates to an application of a cerium oxide nano-material in a vaccine adjuvant and / or a vaccine inactivator, in particular to a vaccine, when the cerium oxide nano-material is the vaccine adjuvant, the vaccine comprises the vaccine adjuvant and an immunogen; or when the cerium oxide nano material is a vaccine inactivating agent, the vaccine is a composite vaccine, the composite vaccine comprises the vaccine inactivating agent and a virus, and the virus is embedded in the cerium oxide nano material; the preparation method of the composite vaccine comprises the step of mineralizing and inactivating viruses by using a vaccine inactivator, wherein the vaccine inactivator is cerium salt. The cerium oxide can be used as a vaccine adjuvant and also can be used as a virus inactivator. The maturation of dendritic cells and macrophages can be promoted by means of regulating the level of active oxygen in immune cells and the like, and the antigen presentation efficiency is improved, so that the vaccine-induced body fluid and cellular immune response is enhanced; meanwhile, cerium salt can directly act on virus surface protein for mineralization, efficient and safe virus inactivation is achieved, and preparation of inactivated vaccines is facilitated.

The technology proposed herein concerns a vaccine formulation comprising a) an antigen comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, and b) a buffer having a pH of 6 to 8 and comprising: a. aluminum hydroxide gel particles, and b. a buffer system comprising: i. 1-3 mM phosphate and 100-200 mM NaCl, or ii. 5-15 mM histidine and 200-400 mM sorbitol. The technology proposed herein further concerns a method of producing a vaccine formulation as well as a vaccine formulation for use in a method of reducing, preventing and / or treating a GBS infection.

The application discloses a kind of biological immobilized enzyme based on yeast surface display technology and the application of synthesis 2-phenylethanol, using yeast surface display technology, for the first time with Saccharomyces cerevisiae surface protein a-lectin as anchor protein, the key enzyme (transaminase, decarboxylase, ethanol dehydrogenase) involved in 2-PE producing Ehrlich pathway in Saccharomyces cerevisiae is separately or jointly carried out biological fixation, enhance substrate channel effect and proximity effect, in vitro one-step catalysis L-phenylalanine synthesis 2-PE, provide yield.The method for fixing multiple enzymes of Ehrlich pathway in the application can be used to reconfigure the biosynthesis pathway of other natural products in vitro, to provide feasible scheme for the rational design of cell factory.

The invention discloses arcanobacterium pyogenes surface protein as well as a screening method and application thereof, and belongs to the technical field of biology. According to the invention, a protective antigen which can be soluble and efficiently expressed in escherichia coli is screened from arcanobacterium pyogenes heparin binding protein, and antigen prediction, solubility analysis and structure-oriented protein design are combined; proteins A0A3Q9GGY1, A0A3S9QKJ0 and a six-site mutant PLO which can be soluble and efficiently expressed in escherichia coli and have good immune protection efficacy are successfully obtained, experience is accumulated for screening and design of high-yield antigens, and a foundation is laid for research and development of arcanobacterium pyogenes vaccines.

This invention discloses a single-chain antibody against the S1 protein on the surface of SARS-CoV-2, comprising a heavy chain sequence and a light chain sequence. The invention also discloses a gene encoding the above sequence, a recombinant vector containing the above gene, a host cell containing the above vector, a biological agent containing the above antibody, and the application of the above antibody against SARS-CoV-2. This effectively solves the problem of a lack of highly potent antibodies against SARS-CoV-2.

Disclosed are a modified nucleic acid aptamer-paclitaxel conjugate, a preparation method therefor, and use thereof. The modified nucleic acid aptamer-paclitaxel conjugate comprises paclitaxel, a succinic acid linker, and an AS1411 aptamer modified with a G4 ligand. In the modified nucleic acid aptamer-paclitaxel conjugate, a nucleic acid aptamer and paclitaxel are coupled by means of a linking bond, and then a target conjugate is obtained by modifying the structure of the nucleic acid aptamer with a G-quadruplex stabilizer using a chemical method. The conjugate has better tumor targeting properties and ultimately specifically targets tumor cell surface proteins, thereby exhibiting anti-cancer activity for the treatment of cancer.

The present invention relates to a recombinant protein comprising one or more fragments of the surface protein A (PspA) of the pneumococcal, and an adenylate cyclase (CyaA) from the genus Bordetella, in particular Bordetella pertussis, in which the fragments of the PspA are selected from the group consisting of clades 1 to 4, or a combination of two or more thereof. Furthermore, the present invention relates to an expression cassette comprising a DNA sequence encoding said recombinant protein, in particular a DNA sequence selected from the nucleotide sequences represented by SEQ ID NO: 12 to 18 and a degenerate sequence thereof, which respectively encode the recombinant protein represented by SEQ ID NO: 5 to 11. In addition, immunogenic compositions comprising the recombinant protein or the expression cassette and further pharmaceutically acceptable carriers and / or adjuvants are disclosed. Finally, the present invention relates to the use of said recombinant protein, said expression cassette or said immunogenic composition for the preparation of a vaccine for the prevention of infection by Streptococcus pneumoniae wherein said vaccine provides broad spectrum protection against different pneumococcal isolates regardless of serotypes.

Provided are innovative compositions for tethering blocking an inactivating of airborne respiratory infectious viruses. The compositions comprise bispecific proteins with two different antigen binding regions (ABR), which are typically configured as immunoglobulin “single variable domains” (ISV). A first ISV binds to a surface protein found on an airborne infectious virus. A second ISV binds to a mucin protein, e.g. a mucin protein present on ocular, nasopharyngeal, tracheal and / or oral surfaces of a mammal. The two ISV are joined by a polypeptide linker.

The present invention relates to the provision of trifunctional crosslinker compounds comprising (i) a moiety reactive with an amino acid side chain for selective labelling of proteins, (ii) a cleavable linker moiety and (iii) an affinity moiety for the detection, isolation and purification of captured proteins. The invention further relates to uses of the cleavable crosslinking reagents in methods for detecting, labelling, identifying and characterizing proteins and protein interactions in or on the surface of intact cells, cell lysates and / or protein mixtures.

The invention belongs to the technical field of biological medicine, and discloses an enteritis targeted probiotic delivery system and a preparation method and application thereof, the system comprises: i) a recombinant plasmid for coding an anti-inflammatory functional protein, the plasmid comprising an anti-inflammatory peptide fragment, a surface protein modification and an antibiotic switch; ii) Escherichia coli chassis bacteria which are subjected to genetic engineering modification and have the capability of high yield of outer membrane vesicles; and iii) introducing the recombinant plasmid into the escherichia coli chassis bacterium to obtain a recombinant engineering bacterium. The delivery system disclosed by the invention can target intestinal inflammation parts, deliver anti-inflammatory proteins through the outer membrane vesicles, and specifically release anti-inflammatory factors in an inflammation microenvironment, so that intestinal inflammation response is relieved; according to the present invention, the method can achieve the precise targeting on the intestinal inflammation, can effectively control the remote delivery and the continuous secretion of the anti-inflammatory protein in space and time, has advantages of strong targeting property, lasting effect, small side effect and the like, and provides the new strategy for the safe and efficient treatment of the intestinal inflammation diseases.

The application provides application of psoralen in activating NK cells. The psoralen provided by the application is a coumarin component extracted from traditional Chinese medicine psoralea; through in-vitro cell experiment verification, the psoralen can activate NK-92 to secrete IFN-gamma, Granzyme B and Perforion, and activate surface protein NKG2D of NK-92; meanwhile, the psoralen also has the same effect on a cell group containing NK cells; through in-vivo experiment verification, the psoralen helps to improve the total amount of NK cells in the mouse spleen, inhibit tumor growth, and improve the expression amount of IFN-gamma, Granzyme B, Perforion, NKG2D, NKP46 and CD107a in a tumor infiltration environment. In summary, the small-molecule compound psoralen has good effect in activating NK cells.

The invention provides a medical instrument humectant and a preparation method thereof. The medical instrument humectant comprises the following components: 5-10 parts of a first anionic surfactant; 1-4 parts of a zwitterionic surfactant; 1-3 parts of a second anionic surfactant; 2 to 5 parts of a polyol humectant; 0.10 to 0.30 part of a first bacteriostatic agent; 0.1 to 0.4 part of an organic phosphonic acid antirust agent; 1-4 parts of a small molecule polyol humectant; 0.01 to 0.08 part of a second bacteriostatic agent; 0.005 to 0.03 part of protease; and the balance of deionized water. According to the present invention, the inhibition rate of common pathogenic bacteria can be improved, and the antibacterial duration can be prolonged; the anti-rust performance is improved; protein residues on the surface of the instrument are efficiently decomposed, meanwhile, a stable moisturizing film is formed, and synergistic cleaning and moisturizing are achieved; the product stability is improved, and layering and precipitation in the storage process are avoided.

Compositions comprising aptamers capable of specifically binding to a surface protein of Clostridium difficile spore are provided. A method for detecting, enriching, separating, and / or isolating Clostridium difficile spores is provided.

The invention discloses application of desoxyribonucleic acid-poly-L-lysine composite hydrogel in redistribution of endogenous exosomes and treatment of myocardial infarction, and the desoxyribonucleic acid-poly-L-lysine composite hydrogel comprises a DNA (deoxyribonucleic acid) skeleton and poly-L-lysine wrapping the DNA skeleton, the DNA skeleton contains a nucleic acid aptamer targeting exosome surface protein, and the desoxyribonucleic acid-poly-L-lysine composite hydrogel is used for capturing and releasing endogenous exosomes. According to the invention, the injectable desoxyribonucleic acid-poly-L-lysine composite hydrogel is used for treating myocardial infarction, and targeted enrichment and controllable release of endogenous exosomes are realized through the unique molecular design of the desoxyribonucleic acid-poly-L-lysine composite hydrogel; important breakthrough is achieved in the aspects of targeting, controllability, safety, clinical transformation and the like, and a brand new solution is provided for myocardial infarction treatment.

The purpose of the present invention is to provide an immunogenic composition containing a new HBV polypeptide or polynucleotides encoding the polypeptide. The immunogenic composition contains at least one polypeptide selected from among polypeptides a) through c) or polynucleotides encoding the polypeptide, and can be used for treating or preventing HBV infection. a) an HBV surface protein polypeptide including a specific amino acid substitution; b) an HBV polymerase polypeptide including an inactivated reverse transcriptase domain and an inactivated ribonuclease H domain, and including a specific amino acid substitution; and c) an HBV core protein polypeptide including a specific amino acid sequence.

Provided herein are methods for highly multi-plexed detection and quantification of co-localized membrane surface proteins. Provided herein are also methods for determining the likelihood that a subject has a disease or condition, such as cancer.

The present invention relates to self-assembling multimeric protein particles displaying Borrelia antigens, namely an encapsulin protein particle displaying an 'outer surface protein A' (OspA) antigen and a DPS (DNA binding protein from starved cells) protein particle displaying a mutant 'complement regulator-acquiring surface protein 2' (CspZ) antigen for use in the vaccination against Lyme disease, particularly in combination.

A method for preventing the retinal pigment from being removed from the network, comprising the steps of pre-fixing liquid fixation, solidifying agent wrapping shaping, fixing liquid fixation, embedding agent embedding, melanin decomposition liquid decomposing melanin, pre-decoloring liquid pre-decoloring, decoloring liquid decoloring and rinsing liquid elution. A method for removing melanin is provided to effectively avoid the retinal RPE layer cell from being removed from the network, protein denaturation and nucleic acid degradation. The method mainly adopts the following steps: pre-fixing liquid to maintain the original state of tissue cells, solidifying agent to maintain the integrity of tissue structure, melanin decomposition liquid composed of various extracts to decompose melanin particles, pre-decoloring liquid and decoloring liquid to separate melanin, and rinsing liquid to elute the decomposed melanin on the surface of the tissue, etc. Under the premise of ensuring the integrity of the retinal tissue structure, not damaging the surface protein, nucleic acid and cell structure of the tissue section, effectively decomposing the melanin particles in the tissue section, maintaining the biological activity of various organelles on the section surface and meeting the needs of subsequent various histochemical staining.

Provided herein are methods for high-plexity EV surface protein characterization. Provided herein are also methods for determining the likelihood that a subject has a disease or condition, such as cancer.

A field of glycoproteomics for identifying novel cell surface O-linked glycopeptide epitopes. The disclosure relates to methods for identifying O-linked glycopeptides, more specifically, Tn- or SiaTn-antigen O-glycosylation sites on cell surface proteins, the method comprising a combined workflow of enzymatic treatments of cells or tissue samples to allow specific enrichment and labelling of Tn antigens, followed by mapping of the O-glycopeptides through LC-MS / MS. More specifically, the disclosure relates to a chemo-enzymatic method to produce labelled O-glycan-peptides from a plasmamembrane-protein extract sample, wherein Sialyltransferase (ST3Gal1 / ST3Gal3) treatment is used to protect free galactose against a follow-on treatment with Galactose oxidase, wherein the oxidized glycans are simultaneously labelled. The disclosure further relates to a tandem mass spectrometry method using an enriched TMT-labelled (Sia)Tn-antigen glycopeptides in a dual fragmentation triggered approach to resolve the identity, localization and quantification of the O-linked glycan peptides.

The present invention provides a novel substance that stably binds to a surface protein expressed on NK cells. The present invention provides a monobody that binds to a surface protein of an NK cell, wherein the monobody has an amino acid sequence of any one of (1) to (3): (1) an amino acid sequence represented by any one of SEQ ID NOs: A1 to A12; (2) an amino acid sequence given by deletion, substitution, and / or addition of one or more amino acids in an amino acid sequence represented by any one of SEQ ID NOs: A1 to A12 excluding arbitrary amino acids; and (3) an amino acid sequence having an identity of 80% or more with an amino acid sequence represented by any one of SEQ ID NOs: A1 to A12 excluding arbitrary amino acid sequences, wherein X1, X2, X3, X4, X5, and X6 in SEQ ID NOs: A1 to A12 each independently represent an arbitrary amino acid, and n1, n2, n3, n4, n5, and n6 each independently represent an arbitrary natural number.X1n1 X2n2 X3n3 (SEQ ID NO: A1)PIWGRYGTTVRGQTYYWWMLX1n1X2n2 X3n3 (SEQ ID NO: A2)WTWLGYEYYWWDSKPGAIGIX1n1 X2n2 X3n3 (SEQ ID NO: A3)TYWDWGFRWSWARRTHISWFX4n4X5n5 X6n6 (SEQ ID NO: A4)PGYYMWQRGVINGQERAYGHPEHFX4n4X5n5 X6n6 (SEQ ID NO: A5)RYKYHRRINGTQWYVFNEAGDVAGYX1n1X2n2 X3n3 (SEQ ID NO: A6)GPIVSYSWWYHWVGYVNEKYDAWQSYVQX1n1X2n2 X3n3 (SEQ ID NO: A7)QAYWFEYTWWLEVVYDDQWTSGX4n4X5n5 X6n6 (SEQ ID NO: A8)TSPWYNGYDQYKSWNLEEFHX4n4X5n5 X6n6 (SEQ ID NO: A9)TPPWIHKGWVTPYGRKWVGMNGWX1n1X2n2 X3n3 (SEQ ID NO: A10)LWHYYGDQYWWMYVPEYYFNPWX1n1X2n2 X3n3 (SEQ ID NO: A11)TDRNYDITYGMQYWWDGYSYSEEAWYYX4n4X5n5 X6n6 (SEQ ID NO: A12)WSWESYWHGTYTFMKDIPSYY

This invention provides compositions containing VHH conjugates and their use in treating diseases. [Solution] (i) A conjugate comprising a single-domain antibody (VHH) conjugated with an antigen and an anti-inflammatory agent, wherein the VHH conjugates the single-domain antibody (VHH) to a surface protein on an antigen-presenting cell (APC); or (ii) A first conjugate comprising VHH conjugated to an antigen, wherein the first VHH and the second VHH bind to one or more surface proteins on an antigen-presenting cell (APC), and a second conjugate comprising the second VHH conjugated to an anti-inflammatory agent, A composition containing the following is provided.

The present disclosure provides methods and compositions for using a novel class of glycan conjugates for modulating cell surface proteins and receptor complexes that can be used to engage signaling pathways within desired cell types. Such defined cell-targeting bioactive glycoligands are directed to cell engagement and activation in therapeutic applications.

A deproteinized natural rubber latex and preparation method thereof are provided. A combined immobilization technology of a multi-enzyme system is introduced to form a multi-enzyme synergistic effect, such that high-concentration enzymes contact with proteins in natural rubber latex. Meanwhile, due to the complexity and diversity of latex proteins, the catalytic properties of different enzymes are effectively combined to realize a multi-enzyme cascade reaction, and the proteins are hydrolyzed gradually and orderly. In addition, an immobilized enzyme filter screen is introduced, and the filter screen is lifted and circulated to make rubber particles collide with high-density enzyme carrier and then complete mixing evenly to reduce damages to the rubber particles when surface proteins are removed, thereby maintaining original physical properties of the latex. The rubber latex has high stability, reusability, is easy for separation and continuous operation, and is environmentally friendly.